Huons Global Reports 131.6 Billion KRW in Q1 Sales... 13% Increase YoY Driven by Strong Performance in Health Supplements

"Hyuns New Dietary Supplement Business, Humedics Aesthetic Business Lead Strong Performance"

[Asia Economy Reporter Kim Ji-hee] Huons Global, the holding company of Huons Group, announced on the 11th that its consolidated operating profit for the first quarter of 2021 increased by 9% year-on-year to 20.5 billion KRW. During the same period, sales grew by 13% to 131.6 billion KRW.

A representative from Huons Global stated, "Huons led the growth in the new health functional food business, while Humedix's main businesses, the aesthetic business and the ophthalmic solution consignment business, drove strong performance," adding, "The subsidiaries of both companies, Huons Natural, Huons Nature, and Huons Medical, also continued their profitability, contributing to the strong results."

Huons recorded consolidated sales of 99.8 billion KRW and operating profit of 13.6 billion KRW in the first quarter, marking increases of 6% and 20% respectively compared to the same period last year. The health functional food business was the main driver of these results. The flagship product, the menopause probiotic ‘Eluvi Menolacto Probiotics,’ achieved sales of 7.4 billion KRW in just one quarter, exceeding 40% of last year's annual sales of 17.4 billion KRW.

Huons Natural and Huons Nature also continued their growth. Huons Natural recorded sales of 3.7 billion KRW, an 8% increase year-on-year, with an operating profit of 58 million KRW. Huons Nature showed sales of 7.6 billion KRW and operating profit of 500 million KRW, up 12% and 112% respectively compared to the previous year.

To strengthen competitiveness in the health functional food business, Huons plans to advance its business model and actively expand its portfolio. Through ‘Huons Mall,’ an online mall dedicated to health functional foods, the company will enter the D2C business to secure competitiveness and introduce various high-quality health functional food products, including new Eluvi Menolacto products.

Additionally, the recently announced contract manufacturing business for the Russian COVID-19 vaccine ‘Sputnik V’ will be further developed.

Yoon Sung-tae, Vice Chairman of Huons Global, said, “The proper balance between our existing core businesses and new ventures enabled stable performance growth across the group in the first quarter. Moving forward, we will continue to faithfully pursue our core businesses while continuously discovering and strengthening new businesses that will contribute to both internal and external growth and improve the group’s profitability.”

This content was produced with the assistance of AI translation services.